XASE · Healthcare · Biotechnology
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-18 | Q1 2026 | -0.05 | -0.05 | +0.00% | $0 | ➖ Inline | -1.00% | +0.64% | -8.51% |
| 2026-03-12 | Q4 2025 | -0.37 | -0.12 | +67.84% | $0 | ✅ Beat | -1.17% | +2.54% | +27.46% |
| 2025-11-12 |
| Q3 2025 |
| -0.38 |
| -0.45 |
| -18.42% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q2 2025 | -0.47 | -1.93 | -310.64% | $0 | ❌ Miss | +0.27% | +4.02% | -2.60% |
| 2025-03-06 | Q4 2024 | — | -1.59 | — | $0 | — | -4.24% | -21.28% | -25.53% |
| 2024-08-13 | Q2 2024 | -7.00 | -5.50 | +21.43% | $0 | ✅ Beat | -6.40% | -35.58% | -30.20% |
| 2024-05-07 | Q1 2024 | -8.50 | -7.50 | +11.76% | $0 | ✅ Beat | +0.24% | -10.53% | -36.00% |
| 2024-03-25 | Q4 2023 | -10.25 | -8.25 | +19.51% | $0 | ✅ Beat | — | — | — |
Showing last 8 quarters.